Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
To explore the effects of lenvatinib in combination with tislelizumab with or without TACE in patients with hepatocellular carcinoma on survival, disease progression, and medication safety.
Hepatocellular Carcinoma
DRUG: Lenvatinib Plus Tislelizumab|DEVICE: Transarterial Chemoembolization(TACE)
Overall response rate (ORR), The proportion of patients in a clinical trial who experience either a complete response (CR), a partial response (PR) as a result of treatment., baseline up to approximately 6 months
Disease control rate(DCR), The proportion of patients in a clinical trial who experience either a complete response (CR), a partial response (PR), or stable disease (SD) as a result of treatment., baseline up to approximately 6 months|Progression free survival (PFS), The length of time that a patient survives without their disease progressing., baseline up to approximately 12 months|Overall response (OS), The length of time that a patient survives from the start of treatment until death from any cause., baseline up to approximately 12 months|Duration of Overall Response (DOR), The length of time that a patient experiences a complete or partial response to treatment., baseline up to approximately 6 months|3-month/6-month PFS rate, The proportion of patients who survive without their disease progressing for at least 3/6 months after the start of treatment., At the time of 3-month/6-month|6-month/12-month OS rate, The proportion of patients who survive for at least 6/12 months after the start of treatment., At the time of 6-month/12-month|Conversion surgery rate, The proportion of the patients who recieved the conversion surgery., baseline up to approximately 12 months
To explore the effects of lenvatinib in combination with tislelizumab with or without TACE in patients with hepatocellular carcinoma on survival, disease progression, and medication safety.